Start the conversation
Juno Therapeutics Inc. (Nasdaq: JUNO) develops therapies for different types of lymphomas, leukemias, and other cancers. Through its IPO, JUNO wants to raise $153 million by selling 9.3 million shares at a $15 to $18 range. After the deal, JUNO will have a market cap near $1.5 billion. The IPO comes at a time when the biotech market is heating up. Since mid-October, the Nasdaq Biotechnology Index (Nasdaq: NBI) has gained 18% since mid-October. JUNO stock debuts Friday, Dec. 19.